companiesCompany
MacroGenics
MacroGenics is the antibody engineering company behind margetuximab and several bispecific and ADC programmes.
Fc-optimisation and DART bispecific platforms; margetuximab (Margenza, 2020); vobramitamab duocarmazine (B7-H3 ADC) paused after toxicity; lorigerlimab (PD-1×CTLA-4).